Subsequent in vitro and in vivo studies confirmed NP accumulation in cancer cells, attributed to the CD44-targeting property of HA, thus enhancing NP uptake into cancer cells, low cytotoxicity, minimal accumulation in other organs, and up to 44% reduction in SET1 expression post-cancer cell lysis [81]. This evidence concerns the gene SETD1A and cancer.